Vaxcyte Inc
PCVX31.750USD
-0.840-2.58%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
4.12BMarket Cap
LossP/E TTM
More Details of Vaxcyte Inc Company
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Company Info
Ticker SymbolPCVX
Company nameVaxcyte Inc
IPO dateJun 12, 2020
CEOMr. Grant E. Pickering
Number of employees414
Security typeOrdinary Share
Fiscal year-endJun 12
Address825 Industrial Road, Ste. 300
CitySAN CARLOS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94070
Phone16508370111
Websitehttps://vaxcyte.com/
Ticker SymbolPCVX
IPO dateJun 12, 2020
CEOMr. Grant E. Pickering
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.32%
The Vanguard Group, Inc.
9.22%
RA Capital Management, LP
9.22%
Fidelity Management & Research Company LLC
7.74%
BlackRock Institutional Trust Company, N.A.
6.97%
Other
55.54%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.32%
The Vanguard Group, Inc.
9.22%
RA Capital Management, LP
9.22%
Fidelity Management & Research Company LLC
7.74%
BlackRock Institutional Trust Company, N.A.
6.97%
Other
55.54%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.86%
Investment Advisor/Hedge Fund
34.47%
Hedge Fund
17.82%
Venture Capital
10.96%
Research Firm
2.30%
Bank and Trust
0.83%
Sovereign Wealth Fund
0.76%
Individual Investor
0.68%
Pension Fund
0.53%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
2023Q1
366
92.70M
119.26%
-1.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
14.54M
11.27%
+2.77M
+23.58%
Apr 30, 2025
The Vanguard Group, Inc.
12.02M
9.32%
+82.12K
+0.69%
Mar 31, 2025
RA Capital Management, LP
12.19M
9.45%
+3.50M
+40.28%
Mar 31, 2025
Fidelity Management & Research Company LLC
10.73M
8.31%
-632.25K
-5.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.13M
7.08%
-112.81K
-1.22%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
2.70M
2.1%
-158.03K
-5.52%
Mar 31, 2025
Wellington Management Company, LLP
6.42M
4.97%
+1.97M
+44.39%
Mar 31, 2025
State Street Global Advisors (US)
4.41M
3.42%
-131.72K
-2.90%
Mar 31, 2025
Capital Research Global Investors
6.11M
4.74%
-100.42K
-1.62%
Mar 31, 2025
Paradigm BioCapital Advisors LP
1.70M
1.32%
+273.69K
+19.24%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
iShares Morningstar Small-Cap ETF
0%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Dow Jones U.S. ETF
0%
Avantis US Equity ETF
0%
ProShares UltraPro Russell2000
0%
Schwab 1000 Index ETF
0%
Proshares Ultra Russell 2000
0%
iShares Morningstar Small-Cap ETF
Proportion0%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
iShares Dow Jones U.S. ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Schwab 1000 Index ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
